TG100801, applied daily in eye drop form, is designed to suppress disease-related edema, angiogenesis and inflammation, which are all pathological hallmarks of macular degeneration.
Currently approved therapies for macular degeneration require repeated injection into the eye and typically act on only VEGF-mediated retinal leakage. TargeGen believes that TG100801 may offer equal or superior efficacy to injectable agents, while offering patients the greater convenience and potential safety advantages of non-invasive delivery. In preclinical testing, TG100801 demonstrated the ability to reduce VEGF-mediated retinal leakage, angiogenesis and inflammation after topical instillation.
“While non-invasive delivery represents a potential major step forward in the treatment of AMD, we believe TG100801 also has the potential to offer superior efficacy by virtue of its more comprehensive mechanism of action, which goes beyond VEGF-mediated retinal leakage,” stated Peter Ulrich, CEO and co-Founder of TargeGen.
The trial is expected to be completed by the end of the first quarter of 2007. The company hopes to initiate phase II studies with TG100801 in mid 2007.